Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Expect results between topical and injectable in terms of magnitude
commonly reported issues from anecdotal and preclinical sources include injection-site irritation, fatigue or flu-like symptoms, muscle tightness/cramps, temporary water retention, and theoretical immune reactions to the PEG component
The peptide is constructed on a GIP receptor backbone with non-coded amino acid residues (Aib2, Aib20, aMeL13) and a C20 fatty diacid moiety that enables albumin binding, extending pharmacokinetic half-life for once-weekly administration in research settings
Category: Recovery Research and documentation guide Testing information Browse all research products Yes
Until rigorous studies show that BPC-157 does not awaken any sleeping dragons (like micrometastases), its best viewed with deep skepticism
Image from the paper of Araj et
